RxDoctor Payments Data

Charles Fillingane, DO

Family Medicine · Maryville, MONPI 1275854465

Payments from drug & device makers

$2,605in general payments, 2019–2025

Across 147 payments — averaging $17.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$907
  • Otsuka America Pharmaceutical, Inc.$327
  • AstraZeneca$295
  • Johnson & Johnson$169
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$157
  • Takeda Pharmaceuticals U.S.A., Inc.$139
  • plus $611 from 13 others

What the payments were for

  • Food & beverage$2,59099%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,605 in reported general payments places this provider in the 75th percentile of 2,203 family medicine providers in Missouri.

See all family medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$136,286
Medicare patients
221
Services billed
2,952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide113$140,072
JardianceEmpagliflozin85$82,391
VraylarCariprazine Hcl26$37,786
OzempicSemaglutide30$36,341
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$32,759
RybelsusSemaglutide19$31,389
EliquisApixaban36$28,441
QuliptaAtogepant18$25,114
TrulicityDulaglutide21$19,434
ArexvyRsvpref3 Antigen/As01e/Pf62$19,030
Tresiba Flextouch U-200Insulin Degludec21$18,683
Tresiba Flextouch U-100Insulin Degludec23$16,241
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl52$15,441
FarxigaDapagliflozin Propanediol20$13,343
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$11,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$13$159,506134 claims
AbbVieVraylar, Qulipta, Linzess$907$71,06457 claims
Novo NordiskOzempic, Rybelsus$38$67,73049 claims
PfizerEliquis, Nurtec Odt$83$39,19247 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$295$33,76472 claims
Johnson & JohnsonXarelto$169$11,04714 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$139$7,48018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,203 family medicine providers in Missouri.

Other family medicine in Maryville

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →